22 May 2013
Keywords: Ambrx, Merck & Co, Technology, Biologic drug conjugates, Collaboration
Article | 19 June 2012
Privately-held California-based Ambrx has entered into a collaboration with US drug giant Merck & Co (NYSE: MRK) to design and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 June 2012
21 May 2013
© 2013 thepharmaletter.com